#218 1960 · Frances Oldham Kelsey / FDA · Pharmaceutical regulationlegibility
The rule said a drug application had to be rejected within 60 days or it was automatically approved — so instead of trying to reject a well-funded drug outright, Kelsey just never let the clock run out.
the problem
the formal process governing a decision is structurally biased toward a default outcome you believe is wrong, and directly overriding that default invites resistance you may not be able to win
background
Under 1960s FDA rules, a New Drug Application was automatically approved for market if the agency's reviewer failed to formally reject it within 60 days of submission — a structure that put the burden on a reviewer to actively stop a drug rather than requiring the manufacturer to actively prove safety, meaning inaction by the FDA defaulted to approval, not caution. Frances Oldham Kelsey, in her first weeks as a new FDA medical officer in September 1960, was assigned to review Merrell Pharmaceuticals' application for thalidomide, a sedative marketed in Europe as safe for pregnant women experiencing morning sickness.
Kelsey found the clinical safety data Merrell submitted unconvincing rather than clearly conclusive — not proof the drug was dangerous, but not proof it was safe either. Rejecting the application outright against a well-funded, aggressive pharmaceutical company with only ambiguous evidence risked a fight she might not win under a regulatory structure built to favor approval by default; Merrell's sales representatives began pressuring her office directly once the delay began.
the move
Rather than issue an outright rejection, Kelsey used the review process's own legitimate mechanism against the default: each time Merrell's submitted safety data fell short of what she considered scientifically adequate, she formally requested additional data, resetting or extending the clock and keeping the application in an unapproved state without ever needing to win a definitive up-or-down confrontation over the drug's safety.
the payoff
Kelsey's repeated requests for better evidence delayed thalidomide's US approval for roughly 19 months, during which independent researchers in Germany and Australia established a clear link between thalidomide and severe birth defects, affecting an estimated several thousand babies born to mothers who had taken the drug in Europe and elsewhere. Thalidomide was never approved or marketed in the United States, sparing American mothers and infants from the disaster unfolding abroad.
what came after
The thalidomide episode, and Kelsey's role in it, directly drove passage of the 1962 Kefauver-Harris Drug Amendments, which fundamentally rewrote US drug approval to require manufacturers to affirmatively prove both safety and efficacy before market approval rather than defaulting to approval absent a rejection — Kelsey is now the textbook case in regulatory and public health circles for how a reviewer can use a biased process's own procedural machinery to hold a line no direct confrontation could have held.
references
- [1]Frances Oldham Kelsey: Medical reviewer famous for averting a public health tragedyUS Food and Drug Administration, 2020fda.gov
- [2]The Devil in the Details, Chapter One: The Doctor Who Said No to ThalidomideScientific American, 2020scientificamerican.com